Cargando…

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus

Detalles Bibliográficos
Autores principales:	Paschou, Stavroula A., Karalis, Vangelis, Psaltopoulou, Theodora, Charitaki, Ioanna, Sklirou, Aimilia D., Iconomidou, Vassiliki A., Vasileiou, Vasiliki, Kassi, Georgia N., Vryonidou, Andromachi, Kokkinos, Alexander, Tentolouris, Nicholas, Hatziaggelaki, Erifili, Trougakos, Ioannis P., Terpos, Evangelos, Dimopoulos, Meletios-Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652043/ https://www.ncbi.nlm.nih.gov/pubmed/36369623 http://dx.doi.org/10.1007/s42000-022-00419-1

Ejemplares similares

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Secondary diabetes mellitus in pheochromocytomas and paragangliomas
por: Moustaki, Melpomeni, et al.
Publicado: (2023)

Hyponatraemia in patients on immune checkpoint inhibitors
por: Paschou, Stavroula A., et al.
Publicado: (2022)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report
por: Vasileiou, Vasiliki, et al.
Publicado: (2021)

Early and late endocrine complications of COVID-19
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Secondary diabetes mellitus in acromegaly
por: Moustaki, Melpomeni, et al.
Publicado: (2023)

Gender differences in COVID-19
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Interplay between baroreflex sensitivity, obesity and related cardiometabolic risk factors (Review)
por: Konstantinidou, Sofia K., et al.
Publicado: (2022)

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
por: Bagratuni, Tina, et al.
Publicado: (2019)

Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity
por: Papanagnou, Eleni‐Dimitra, et al.
Publicado: (2022)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
por: Bagratuni, Tina, et al.
Publicado: (2020)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

Serological testing for SARS-CoV-2: Advancements and future challenges
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Hypokalemia: a clinical update
por: Kardalas, Efstratios, et al.
Publicado: (2018)

Cardiac tamponade in a patient with autoimmune polyglandular syndrome type 2
por: Vryonidou, Andromachi, et al.
Publicado: (2017)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qmnhvc9jsh8cmde8mmc0mm3dmd